AD/PD 2017 Archives - PsychoGenics

Propagation and aggregation of alpha synuclein in murine models

by admin | Jul 10, 2017

S RAMBOZ1 WASHINGTON A1, RAYNEL S1, JASON B1, NICOLE C1, SHEILYN N1, KIMBERLY C1, KIM C1, KENDALL W1. 1PsychoGenics, Tarrytown, NY, USA Aggregation of mis-folded proteins is a feature common to many neurodegenerative diseases. In Parkinson’s disease, characterized...

Phenotypic characterization of a genetically modified animal model of Parkinson’s Disease

by admin | May 24, 2017

S RAMBOZ1, K CIRILLO1, R SPRINGER1, M MAZZELLA, D HAVAS1, K WALKER1, J.A. SANCHEZ-PADILLA1, G TOMBAUGH1, A GHAVAMI1. 1PsychoGenics, Tarrytown, NY, USA PsychoGenics, Inc has acquired a license for a genetically modified α-synuclein mouse line expressing the human...

Cross Comparison Of Neurological Deficits in SOD1 G93A and Profilin 1(PFN1 G118V)Mouse Models of Motor Neuron DIsease

by admin | Mar 14, 2017

I. MORGANSTERN1, N. ROBERTS1, E. SABATH1, M. KIAEI2, T. HANANIA1. 1PsychoGenics, Tarrytown, NY, USA; 2Department of Pharmacology and Toxicology, Department of Neurology, Department of Geriatrics, The Center for Translational Neuroscience, The University of Arkansas...

Propagation and aggregation of alpha synuclein in murine models

Phenotypic characterization of a genetically modified animal model of Parkinson’s Disease

Cross Comparison Of Neurological Deficits in SOD1 G93A and Profilin 1(PFN1 G118V)Mouse Models of Motor Neuron DIsease

Recent Comments

CONTACT